Korean biopharmaceutical company Medytox is making significant strides in the Middle East, a rapidly growing market often referred to as “Pharmerging,” which combines “pharmacy” and “emerging.” This region is becoming increasingly attractive for biopharmaceutical companies due to its young population and strong purchasing power in cosmetic medicine.

A Booming Market for Cosmetic Procedures

The Middle East and Africa (MEA) are witnessing a remarkable growth in the non-invasive cosmetic procedures market, which expanded by 12.1% and is projected to reach a staggering $6.4 billion by 2030, according to global market research firm Grand View Research. This growth is fueled by a rising interest in cosmetic treatments, particularly among the region’s youth.

Medytox’s Success in Saudi Arabia

Medytox has already established a strong foothold in Saudi Arabia, one of the largest Botox markets globally. Its Botox formulation, Meditoxin (known internationally as Siax), has captured an impressive 30% market share. The demand for cosmetic treatments in Saudi Arabia has surged, driven by cultural shifts and greater freedom in women’s fashion choices.

Expanding into the United Arab Emirates

In addition to its success in Saudi Arabia, Medytox is also expanding its operations in the United Arab Emirates. In May 2024, the company signed a letter of intent with Dubai Science Park (DSP), a subsidiary of the UAE state-owned Tecom Group, to establish a Botox manufacturing facility. This facility aims to be the first halal-certified toxin production site built by a Korean company overseas, targeting both the Middle Eastern and European markets with its innovative non animal derived liquid toxin, MT10109L. This product’s manufacturing process eliminates animal-based components, significantly reducing the risk of animal-borne virus transmission.

Introducing Neuramis: A High-Quality Filler

Beyond Botox, Medytox is also enhancing its presence in the Middle East with its hyaluronic acid filler, Neuramis. Known for its exceptional quality, Neuramis received regulatory approval in Saudi Arabia in 2023 and in the UAE in 2024, quickly becoming a popular choice among consumers in the region.

A Diverse Portfolio of Toxin Products

Medytox stands out as the only company in the world with a diverse portfolio of four different botulinum toxin products: Meditoxin, Innotox, Coretox, and Newlux. To ensure sustainable growth, the company is committed to developing new toxin pipelines that cater to the evolving needs of the market.

Innovations in Aesthetic Medicine

At the upcoming IMCAS World Congress 2025, a leading conference in aesthetic medicine, Medytox will unveil PF30, a prefilled syringe version of MT10109L designed for enhanced safety and efficiency. Additionally, the company will introduce MT951, a DNA-recombinant toxin that boasts a 30% longer durability compared to its competitors.

Aiming for Global Leadership

A representative from Medytox stated,

“We are focused on expanding into international markets and differentiating our products. Our goal is to become a global leader in the botulinum toxin industry.”

With its innovative products and strategic expansions, Medytox is well on its way to achieving this ambitious goal, solidifying its position in the booming beauty market of the Middle East.

Original Article:

Korea JoongAng Daily. (2025, April 27). Medytox tightens its hold on the Middle East’s beauty boom. https://koreajoongangdaily.joins.com/news/2025-02-17/business/guestReports/Medytox-tightens-its-hold-on-the-Middle-Easts-beauty-boom/2243553